UA129777C2 - Солі сполуки та їхні кристалічні форми - Google Patents
Солі сполуки та їхні кристалічні формиInfo
- Publication number
- UA129777C2 UA129777C2 UAA202201538A UAA202201538A UA129777C2 UA 129777 C2 UA129777 C2 UA 129777C2 UA A202201538 A UAA202201538 A UA A202201538A UA A202201538 A UAA202201538 A UA A202201538A UA 129777 C2 UA129777 C2 UA 129777C2
- Authority
- UA
- Ukraine
- Prior art keywords
- salt
- formula
- cancer
- compound
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910973785 | 2019-10-14 | ||
| PCT/CN2020/120594 WO2021073494A1 (en) | 2019-10-14 | 2020-10-13 | The salts of a compound and the crystalline forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA129777C2 true UA129777C2 (uk) | 2025-07-30 |
Family
ID=75537486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202201538A UA129777C2 (uk) | 2019-10-14 | 2020-10-13 | Солі сполуки та їхні кристалічні форми |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12559472B2 (enExample) |
| EP (1) | EP4045484A4 (enExample) |
| JP (2) | JP2022552329A (enExample) |
| KR (1) | KR20220088712A (enExample) |
| CN (3) | CN114555558B (enExample) |
| AR (1) | AR120202A1 (enExample) |
| AU (1) | AU2020367905A1 (enExample) |
| BR (1) | BR112022007035A2 (enExample) |
| CA (1) | CA3154064A1 (enExample) |
| IL (1) | IL292206B2 (enExample) |
| MX (1) | MX2022004274A (enExample) |
| TW (1) | TWI895290B (enExample) |
| UA (1) | UA129777C2 (enExample) |
| WO (1) | WO2021073494A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022411531B2 (en) * | 2021-12-13 | 2025-01-16 | Abbisko Therapeutics Co., Ltd. | Fgfr4 inhibitor acid salt, preparation method therefor, and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| US20160052926A1 (en) * | 2013-03-15 | 2016-02-25 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| CN107660200B (zh) * | 2015-04-14 | 2022-01-11 | 卫材R&D管理有限公司 | 结晶fgfr4抑制剂化合物和其用途 |
| TW201833112A (zh) * | 2016-12-01 | 2018-09-16 | 大陸商和記黃埔醫藥（上海）有限公司 | 化合物的晶型 |
-
2020
- 2020-10-13 BR BR112022007035A patent/BR112022007035A2/pt unknown
- 2020-10-13 AU AU2020367905A patent/AU2020367905A1/en active Pending
- 2020-10-13 US US17/768,951 patent/US12559472B2/en active Active
- 2020-10-13 UA UAA202201538A patent/UA129777C2/uk unknown
- 2020-10-13 WO PCT/CN2020/120594 patent/WO2021073494A1/en not_active Ceased
- 2020-10-13 TW TW109135330A patent/TWI895290B/zh active
- 2020-10-13 JP JP2022522343A patent/JP2022552329A/ja active Pending
- 2020-10-13 KR KR1020227014838A patent/KR20220088712A/ko active Pending
- 2020-10-13 AR ARP200102815A patent/AR120202A1/es unknown
- 2020-10-13 EP EP20876200.5A patent/EP4045484A4/en active Pending
- 2020-10-13 CN CN202080071856.1A patent/CN114555558B/zh active Active
- 2020-10-13 CN CN202411778340.7A patent/CN119462616A/zh active Pending
- 2020-10-13 MX MX2022004274A patent/MX2022004274A/es unknown
- 2020-10-13 CA CA3154064A patent/CA3154064A1/en active Pending
- 2020-10-13 IL IL292206A patent/IL292206B2/en unknown
- 2020-10-13 CN CN202411784884.4A patent/CN119751422A/zh active Pending
-
2025
- 2025-06-24 JP JP2025106308A patent/JP2025143319A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025143319A (ja) | 2025-10-01 |
| CN119462616A (zh) | 2025-02-18 |
| CN114555558B (zh) | 2024-12-17 |
| IL292206A (en) | 2022-06-01 |
| BR112022007035A2 (pt) | 2022-06-28 |
| US12559472B2 (en) | 2026-02-24 |
| WO2021073494A1 (en) | 2021-04-22 |
| IL292206B2 (en) | 2026-03-01 |
| EP4045484A4 (en) | 2023-09-06 |
| AR120202A1 (es) | 2022-02-02 |
| CA3154064A1 (en) | 2021-04-22 |
| KR20220088712A (ko) | 2022-06-28 |
| TWI895290B (zh) | 2025-09-01 |
| AU2020367905A1 (en) | 2022-04-21 |
| JP2022552329A (ja) | 2022-12-15 |
| CN114555558A (zh) | 2022-05-27 |
| US20230121346A1 (en) | 2023-04-20 |
| TW202128669A (zh) | 2021-08-01 |
| IL292206B1 (en) | 2025-11-01 |
| EP4045484A1 (en) | 2022-08-24 |
| CN119751422A (zh) | 2025-04-04 |
| MX2022004274A (es) | 2022-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6752715B2 (ja) | 組合せ | |
| JP6880023B2 (ja) | 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用 | |
| KR20170032330A (ko) | Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 | |
| CN106604919B (zh) | 6-((6,7-二甲氧基喹唑啉-4-基)氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型 | |
| EP2684877A2 (en) | Pharmaceutically acceptable salt of (e)-n-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation method therefor, and medical use thereof | |
| JP2018531280A6 (ja) | 改善された特性を有するβ−グアニジノプロピオン酸の薬学的に許容される塩及びその使用 | |
| KR20170082650A (ko) | 1-(2-디옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 염 | |
| WO2023216910A1 (zh) | 取代的双环杂芳基化合物作为usp1抑制剂 | |
| WO2019001379A1 (zh) | 用于抑制激酶活性的吲唑类化合物及其组合物及应用 | |
| EP4717689A2 (en) | Crystalline forms of quinazoline derivatives, preparation, composition and use thereof | |
| JP2025143319A (ja) | 化合物の塩及びその結晶形態 | |
| CA3239187A1 (en) | Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof | |
| TWI888447B (zh) | 金屬鹽及其用途 | |
| US20260138967A1 (en) | The salts of a compound and the crystalline forms thereof | |
| EA046831B1 (ru) | Соли соединения и их кристаллические формы | |
| US20240360101A1 (en) | Pharmaceutical salts of a chk-1 inhibitor | |
| WO2026026904A1 (en) | The crystalline forms of a compound | |
| TW201833112A (zh) | 化合物的晶型 | |
| EP4289420A2 (en) | Crystalline modifications of n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts | |
| HK40068973A (en) | The salts of a compound and the crystalline forms thereof | |
| HK40077267A (en) | Metal salts and uses thereof | |
| HK40122795A (zh) | 化合物的盐及其晶型 | |
| TW202432111A (zh) | 化合物的晶型及其製備方法和用途 | |
| HK40120202A (zh) | 化合物的盐及其晶型 | |
| HK40095416A (zh) | 取代的双环杂芳基化合物作为usp1抑制剂 |